Our innovative formulations are designed to overcome the Blood-Brain Barrier (BBB), enabling the targeted delivery of Central Nervous System (CNS)-based pharma-therapeutics. This approach aims to enhance drug efficacy and optimize patient outcomes.
Meet NEO100
NEO100 is a highly purified form of Perillyl Alcohol (POH), a natural compound shown to interfere with dividing cancer cells. Research indicates POH’s antitumor activity in various cancers in lab and animal studies, with an inhaled form demonstrating preliminary safety and effectiveness in recurrent gliomas.
Brain and nervous system cancers are devastating, affecting over 300,000 people globally each year and causing more than 240,000 deaths. These include aggressive Grade IV gliomas, which often impact children and young adults and have very low survival rates.
In response to this urgent unmet need, NEO100 is now being tested as an intranasal delivery molecule specifically for treating Grade IV gliomas. Its demonstrated efficacy in recurrent gliomas positions NEO100 as a promising new approach to confront these challenging diseases.
NEO212
NEO212 represents a significant advancement, chemically conjugating Temozolomide (TMZ), the gold-standard DNA alkylating agent for aggressive brain cancers like glioblastoma multiforme (GBM), with our highly purified Perillyl Alcohol (POH). Brain tumors alone account for 85% to 90% of all primary central nervous system (CNS) tumors. While TMZ is vital, its oral and IV delivery faces hurdles: systemic dilution, limited brain uptake due to the Blood-Brain Barrier, and severe side effects, including bone marrow suppression.
Designed for enhanced intranasal delivery via our patented POH technology, NEO212 aims to significantly improve TMZ’s efficacy. This novel approach bypasses traditional systemic routes, allowing for more targeted drug delivery to brain tumors. Ultimately, NEO212 seeks to optimize patient outcomes by boosting treatment effectiveness while simultaneously minimizing TMZ’s burdensome side effects.